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Summary
 
Most tumor cells function poorly as antigen-presenting cells in part because they do not express
costimulatory molecules. To provide costimulation to T lymphocytes that recognize tumor
 
cells, we constructed a CD28-like receptor specific for G
 
D2
 
, a ganglioside overexpressed on the
surface of neuroblastoma, small-cell lung carcinoma, melanoma, and other human tumors.
Recognition of G
 
D2
 
 was provided by a single-chain antibody derived from the G
 
D2
 
-specific
monoclonal antibody 3G6. We demonstrate that the chimeric receptor 3G6-CD28 provides
CD28 signaling upon specific recognition of the G
 
D2
 
 antigen on tumor cells. Human primary
T lymphocytes retrovirally transduced with 3G6-CD28 secrete interleukin 2, survive proapop-
totic culture conditions, and selectively undergo clonal expansion in the presence of an antiid-
 
iotypic antibody specific for 3G6-CD28. Polyclonal CD8
 
1
 
 lymphocytes expressing 3G6-CD28
are selectively expanded when cultured with cells expressing allogeneic major histocompatibil-
ity complex class I together with G
 
D2
 
. Primary T cells given such an antigen-dependent sur-
vival advantage should be very useful to augment immune responses against tumor cells.
Key words: adoptive cell therapy • chimeric receptors • costimulation • ganglioside • gene 
transfer
 
T
 
he challenge for cancer immunotherapy is to elicit and
amplify vigorous immune responses against poorly im-
munogenic tumor cells that mostly express self-antigens (1–
3). Until now, most forms of immunotherapy have aimed
to prime and expand tumor-reactive lymphocytes in vivo
(4, 5). Alternatively, adoptive antibody and cell therapies
are based on the infusion of preformed immune effectors,
whether antibodies (e.g., antibodies against the G
 
D2
 
 antigen
in neuroblastoma [6]) or lymphocytes (7–10). In principle,
adoptive cell therapies are attractive in that they bypass
many of the obstacles to the selective expansion of tumor-
reactive lymphocytes in vivo by enabling their expansion in
vitro. However, the generation of tumor-specific lympho-
cytes on one hand, and the sustained activity of cultured
lymphocytes upon infusion in the recipient on the other,
pose numerous problems (8). Adoptively transferred lym-
phocytes are indeed prone to cell death secondary to cy-
tokine withdrawal, anergy secondary to inappropriate anti-
gen presentation or downregulation of the TCR or other
critical coreceptors. The engagement of the TCR is neces-
sary to activate T cells, but not sufficient to achieve full ac-
tivation. A second signal, or costimulation, is also required
(11–13). The interaction of the T cell surface receptor
CD28 with the costimulatory ligands B7.1 and B7.2 ex-
pressed by professional APCs can induce a strong costimu-
latory signal resulting in the clonal expansion of activated T
cells (14–17). Thus, the costimulatory molecules expressed
by the APC play a major role in determining whether sur-
vival, activation, or cell death will result from the interac-
tion between the T lymphocyte and the APC (12–14).
CD28 signaling in T cells can prevent cell death secondary
to either IL-2 withdrawal or TCR-mediated activation
(15–17).
The absence of natural costimulatory molecules on tu-
mor cells creates unfavorable conditions for the survival
and activation of tumor-reactive T cells (13, 18–23). Dif-
ferent approaches can be taken to provide costimulation to
tumor-specific T lymphocytes. One is to express B7 in tu-
mor cells (5, 24). However, the provision of costimulation
in vivo by genetically modified tumor cells is confined to a
small fraction of the total tumor burden. The success of this
approach critically depends upon the ability to specifically
target B7 expression to a sizable fraction of the tumor cells.
It also depends on the sustained expression of CD28 by the
activated T lymphocytes. On the other hand, the introduc-
tion in tumor-reactive T lymphocytes of a CD28-like re-
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ceptor that is engaged by a tumor-associated antigen and
expressed under the control of the retroviral LTR repre-
sents an alternative approach. The high efficiency gene
transfer that is now achieved in human primary PBLs (25,
26) makes this approach technically feasible.
To enhance the survival and expansion of T lympho-
cytes reacting against tumor cells that lack costimulatory
molecules but express a well-defined cell-surface antigen,
we engineered a chimeric molecule that combines an anti-
gen-specific single chain variable region fragment (scFv)
 
1
 
with the signal transduction domain of CD28. We rea-
soned that an scFv-CD28 fusion molecule could specifi-
cally recognize the cell-surface epitope and mediate CD28
signaling functions, and thus mimic CD28/B7 interactions
between T lymphocytes and tumor cells. The expression of
an antigen-dependent CD28 receptor by adoptively trans-
ferred lymphocytes is expected to increase the probability
that a T cell will survive and perhaps continue to prolifer-
ate when its TCR is engaged by target cells expressing the
cell-surface antigen. The antigen-binding moiety we used
was derived from the mAb 3G6 specific for the disialogan-
glioside G
 
D2
 
 (27), an antigen abundantly expressed by neu-
roblastoma, small-cell lung carcinoma, melanoma, and some
other tumors (6). Highly efficient retroviral-mediated gene
transfer (25, 26) enabled us to study the 3G6-CD28 fusion
molecule in primary T cells rather than in cell lines or leu-
kemic cells. We demonstrate that this receptor engages tu-
mor-associated G
 
D2
 
 antigen and mediates effective CD28
signaling in primary T lymphocytes. Polyclonal CD8
 
1
 
 PBLs
expressing 3G6-CD28 are selectively expanded when cul-
tured with cells expressing MHC class I together with G
 
D2
 
.
Thus, the transduced lymphocytes carry out a functional co-
stimulatory response that enhances their survival and leads to
their selective expansion in the absence of natural costimu-
latory molecules.
 
Materials and Methods
 
Recombinant DNA Constructs.
 
The chimeric cDNA 3G6-CD28
comprises sequences encoding an scFv derived from the G
 
D2
 
-spe-
cific antibody 3G6 (27, 28) and the portion of the CD28 comprising
part of the extracellular, the transmembrane, and the cytoplasmic
domains. The V
 
L
 
 and V
 
H
 
 cDNAs were cloned in that order sepa-
rated by a glycine-rich linker and downstream of the human
CD8
 
a
 
 leader (G. Rothschild, N.K. Cheung, and M. Sadelain,
unpublished observations). The CD28 coding sequence extend-
ing from nucleotide 336 to 663 was amplified by reverse tran-
scription PCR from RNA isolated from the human leukemic T
cell line Jurkat using the forward primer 5
 
9
 
-GCGGCCGCAAT-
TGAAGTTATGTATCCT and the reverse primer 5
 
9
 
-TCGAG-
GATCTTGTCAGGAGCGATAGGCTGC. The primers con-
tain NotI and BamHI sites for the insertion of the PCR product
3
 
9
 
 to the V
 
L
 
 and V
 
H
 
 domains of 3G6 in the retroviral vector SFG
(29). The truncated form 3G6-CD28TR was engineered by
 
PCR, preserving only the three first cytoplasmic amino acids after
the transmembrane domain (reverse primer 5
 
9
 
-CCCACTCCTC-
ATTCATTGCCCTAGGAGCTCGCC). The cDNAs encoding
G
 
D3
 
-synthase (C. Tan and M. Sadelain, unpublished observations),
B7.1 (J.-B. Latouche and M. Sadelain, unpublished observations),
and HLA A2.1 (our unpublished observations; the HLA A2.1
cDNA was provided by Dr. S.Y. Yang, Sloan-Kettering Institute
for Cancer Research) were cloned in the SFG vector as well.
 
Cells.
 
Producer cells derived from the packaging cell line
PG13 (American Tissue Culture Collection, Rockville, MD
[30]) were maintained in DMEM supplemented with glutamine,
penicillin, streptomycin (GIBCO BRL, Gaithersburg, MD), and
10% fetal bovine serum (Sigma Chemical Co., St. Louis, MO).
The Jurkat T cell line E.6 (American Type Culture Collection) as
well as the G
 
D2
 
1
 
 tumor cell line EL4 (American Type Culture
Collection) and its G
 
D2
 
2
 
 variant (31) were grown in RPMI 1640
(GIBCO BRL) supplemented with glutamine, penicillin, strepto-
mycin, and 10% fetal bovine serum. NIH 3T3 fibroblasts (Ameri-
can Type Culture Collection) were cultured in DMEM supple-
mented with glutamine, penicillin, streptomycin (GIBCO BRL),
and 10% donor calf serum (Sigma Chemical Co.). The coculture
experiments of T cells and irradiated fibroblasts were carried out
in AIMV medium (GIBCO BRL) supplemented with 5% donor
calf serum.
 
Retroviral Gene Transfer.
 
High-titer producer cells were gen-
erated from the PG13 packaging cell line as described elsewhere
(32). Individual PG13/3G6-CD28 clones were expanded and ti-
trated on A549 cells by FACS
 
Ò
 
 analysis as described (25). The
clone PG13/3G6-CD28.12 had a titer of 7 
 
3
 
 10
 
5
 
 infectious par-
ticles/ml, and the clone PG13/3G6-CD28TR.55 had a titer of
5 
 
3
 
 10
 
5
 
 infectious particles/ml. The vector SFG-NTP, encoding
an inactive mutant of the human low-affinity growth factor re-
ceptor (LNGFR), and the PG13/NTP.6 producer cell line are
described elsewhere (25). Retroviral infection of Jurkat cells and
human PBLs was carried out as described (26). In brief, PBMCs
from healthy donors were separated on Ficoll activated with
PHA, and exposed to retroviral particles for 18 h in the presence
of polybrene (4 
 
m
 
g/ml). After retroviral infection, the cells were
cultured in the presence of 10 U/ml IL-2 (Cetus Corp., Berke-
ley, CA), and the medium was changed every 3 d. Gene-modi-
fied fibroblasts were transduced as described elsewhere (32) and
selected for expression of HLA A2.1, B7.1, and/or G
 
D2
 
 (J.-B.
Latouche and M. Sadelain, unpublished observations).
 
Antibodies.
 
The purified rat antiidiotypic mAb A1G4 directed
at the antigen-binding site of 3G6, the purified mouse anti-G
 
D2
 
antibody 3F8, and the corresponding F(ab
 
9
 
)
 
2
 
 fragment were de-
scribed earlier (31, 33). Other antibody reagents included 20.4
hybridoma supernatant (mouse anti-LNGFR; American Type
Culture Collection); 9.3 ascites (mouse anti–human CD28; pro-
vided by Dr. B. Dupont, Sloan-Kettering Institute for Cancer
Research); OKT3 (mouse anti–human CD3; Ortho Diagnostic
Systems, Inc., Raritan, NJ); unconjugated, PE–conjugated goat
anti–mouse IgG (GAM-PE) or anti–rat IgG (GAR-PE), FITC-
conjugated goat anti–mouse IgG (GAM-FITC) or anti–rat IgG
(GAR-FITC) antibodies (Caltag Laboratories, Inc., San Fran-
cisco, CA); conjugated mouse anti–human CD8 antibody (CD8-
FITC and CD8-PE) and conjugated mouse anti–human CD25
(CD25-PE) antibody (Becton Dickinson, San Jose, CA).
 
FACS
 
Ò
 
 Analysis.
 
Cell surface expression of transduced cells
was determined by incubating 10
 
6
 
 cells with the antiidiotypic
mAb A1G4 or the anti-LNGFR mAb 20.4 on ice for 30 min,
followed by washing and incubation with the conjugated second-
ary antibodies. For staining the T lymphocytes, a 20-min incuba-
 
1
 
Abbreviations used in this paper:
 
 GAM, goat anti–mouse; GAR, goat anti–
rat; LNGFR, low-affinity nerve growth factor receptor; NTP, inactive
mutant form of the human LNGFR; scFv, single chain variable region
fragment. 
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tion with CD8-FITC, CD8-PE, or CD25-PE antibody was fol-
lowed after blocking with unconjugated mouse serum. G
 
D2
 
 was
detected by incubation with mouse anti-G
 
D2
 
 mAb 3F8 and
GAM-PE antibody. Samples were acquired and analyzed with a
FACScan
 
Ò
 
 (Becton Dickinson).
 
IL-2 Secretion and IL-2R Expression.
 
Duplicate samples of trans-
duced Jurkat (5 
 
3 
 
10
 
4
 
/well) were stimulated in a 96-well plate in
200 
 
m
 
l RPMI medium with soluble antiidiotype mAb A1G4 (2
 
m
 
g/ml), mAb 9.3 (1:1,000), or with EL4 or EL4
 
GD2
 
2
 
 cells in the
presence of OKT3 (10 
 
m
 
g/ml), cross-linked by sheep anti–mouse
beads (3 beads/cell; Dynal Inc., Lake Success, NY). Blocking of
cell-surface G
 
D2
 
 was achieved by preincubating cells with the
G
 
D2
 
-specific 3F8 F(ab
 
9
 
)
 
2
 
 fragment (10 
 
m
 
g/ml). After 24 h, cell su-
pernatants were harvested and tested for IL-2 content by solid-
phase ELISA (Genzyme Corp., Cambridge, MA). In experiments
with human T lymphocytes, 10
 
5
 
 T cells transduced with 3G6-
CD28, 3G6-CD28TR, or NTP were grown overnight in 1 ml me-
dium without IL-2, and incubated the next day with or without
saturating amounts of mAbs in 24-well plates. After 24 h half of
the cells were analyzed for IL-2R
 
a
 
 expression (CD25) by FACS
 
Ò
 
,
and after 48 h the supernatants were tested for IL-2 concentration
by ELISA.
 
Induction of Apoptosis and Assessment of Viability.
 
24-well-clus-
ter tissue culture plates were coated with GAM IgG and GAR
IgG (10 
 
m
 
g/ml) in 300 
 
m
 
l/well 0.05 M carbonate buffer (pH 9.6)
overnight at 4
 
8
 
C. Plates were washed three times with PBS and
overlaid with OKT3 (2 
 
m
 
g/ml PBS, 300 
 
m
 
l/well) for 1 h at
37
 
8
 
C. Plates were washed three times with PBS, and T lympho-
cytes were added at a concentration of 6 
 
3 
 
10
 
5
 
/300 
 
m
 
l RPMI/
10% FCS in the presence of IL-2 (10 U/ml) and mAb 9.3 (1:
1,000) or mAb A1G4 (1 
 
m
 
g/ml). After 3 d of incubation in a hu-
mified atmosphere of 5% CO
 
2
 
 at 37
 
8
 
C, T cells were released
from the cross-linking conditions and kept for 2 d in the presence
of 10 U/ml IL-2. Percentage of live cells relative to total cell
number (percent viability) was determined on day 3 by counting
cells stained in trypan blue (GIBCO BRL) and quantitated by
FACS
 
Ò
 
 analysis using forward and side scatter parameters.
 
Expansion of Transduced T Cells.
 
10
 
6
 
 T cells were first plated
in the presence of OKT3 (10 ng/ml) and 9.3 (1:1,000) or A1G4
(1 
 
m
 
g/ml). After 3 d of culture, the T cells were washed and re-
plated for 3 d in T cell medium containing 10 U/ml of IL-2. This
cycle was repeated once more on days 7–12. In the coculture ex-
periments, 10
 
6
 
 T cells were cultured for 3 d in medium supple-
mented with IL-2 in 24-well plates on an irradiated (10 Gy)
monolayer of genetically modified NIH 3T3 fibroblasts seeded at
a density of 5 
 
3 
 
10
 
4
 
/well. T lymphocytes were added at a con-
centration of 10
 
6
 
/ml. After 3 d of coculture, the T cells were kept
for 3 d in fresh T cell medium containing 10 U/ml of IL-2. This
cycle was repeated once more on days 7–12. On day 6 and 12,
the percentage of transduced T cells was determined by FACS
 
Ò
 
analysis.
 
Results and Discussion
 
Antiidiotypic Antibody and Tumor-associated G
 
D2
 
 Antigen
Specifically Induce IL-2 Secretion in Jurkat Cells that Express
3G6-CD28.
 
We constructed a chimeric receptor encom-
passing most of the human CD28 receptor fused to the
scFv derived from the G
 
D2
 
-specific mAb 3G6 (see Materials
and Methods). The fusion cDNA was cloned into the SFG
vector (29) as described (32), thus placing transcription un-
der the control of the Moloney murine leukemia virus
 
LTR. The full-length protein (36 kD in NIH 3T3 fibro-
blasts and 
 
z
 
40 kD in Jurkat cells) was expressed as a dimer
as demonstrated by Western blot analysis using a polyclonal
antibody directed against the cytoplasmic tail of CD28
(data not shown). Jurkat cells were transduced using re-
combinant retrovirus pseudotyped with the GaLV enve-
lope as described previously (26). The transduced cells
stained positive by FACS
 
Ò
 
 analysis with the antiidiotypic
antibody A1G4, one of five different antiidiotypic antibod-
ies that specifically recognize the mAb 3G6 as well as the
3G6-CD28 fusion protein (data not shown).
The CD28 function of 3G6-CD28 was first evaluated in
a transduced Jurkat clone (obtained by limiting dilution)
that harbored one intact copy of the vector as shown by
Southern blot analysis (data not shown). The engagement
of the 3G6-CD28 receptor by the antiidiotypic mAb
A1G4 in transduced Jurkat cells appropriately triggered the
earliest events of the CD28 signaling pathway (34), includ-
ing the association of the 85-kD regulatory subunit of the
phosphatidylinositol 3-kinase with the phosphorylated form
of the fusion molecule (data not shown). We next investi-
gated the function of 3G6-CD28 in the potentiation of IL-2
secretion, a later event of T cell activation (35, 36). Jurkat
cells transduced with 3G6-CD28, 3G6-CD28TR (derived
from 3G6-CD28 by truncation of the cytoplasmic tail to
disable CD28 signaling [37, 38]), or NTP (25) were stimu-
lated by immobilized anti-CD3 mAb to provide the first
signal for T cell activation. Costimulation was provided by
the addition of anti-CD28 mAb 9.3, by antiidiotypic mAb
A1G4, or by short-term cocultivation (39) with wild-type
EL4 cells which express G
 
D2
 
 (Fig. 1 
 
b
 
). As shown in Table
1, coincubation of EL4 with 3G6-CD28/Jurkat cells led to
IL-2 secretion in a cell dose–dependent manner. EL4 cells
had no stimulatory effect on 3G6-CD28TR/Jurkat and
NTP/Jurkat. Coincubation with G
 
D2
 
2
 
 EL4 (Fig. 1 
 
c
 
) had
no effect on any of the cell lines. Furthermore, the costim-
ulatory effect of wild-type EL4 was completely abolished
by the addition of G
 
D2
 
-specific F(ab
 
9
 
)
 
2
 
. Anti-CD3 antibody
alone had very little effect on Jurkat cells except those ex-
pressing 3G6-CD28 (Table 1). This modest IL-2 secretion
could be explained by the low level of G
 
D2
 
 expression by
Jurkat cells (Fig. 1 
 
a
 
) that leads to CD28 signaling by the
cell–cell interaction through the fusion molecule. Indeed,
Figure 1. GD2 expression in Jurkat and EL4 cells. Cells were stained
with mAb 3F8 (solid line) or isotype-matched mAb 20.4 (broken line), di-
rected against GD2 and human LNGFR, respectively. (a) Jurkat cells; (b)
wild-type EL4; (c) EL4GD22. The three cell lines are, respectively, GD2
low,
GD2
1, and GD2
2. GD2 expression by these cells is closely correlated with
the costimulatory activity described in Table 1.622 Antigen-dependent Costimulation Selectively Enhances Lymphocyte Survival
the addition of GD2-specific F(ab9)2 to CD3-stimulated
3G6-CD28/Jurkat cells reduced IL-2 secretion below the
level elicited by anti-CD3 mAb alone (Table 1). These re-
sults indicate, first, that 3G6-CD28 specifically recognizes
cell-surface GD2 antigen and, second, that recognition of
tumor-associated GD2 leads to effective CD28-dependent
signaling, including IL-2 secretion.
Stimulation of Human Primary CD31 T Lymphocytes Ex-
pressing the Fusion Molecule 3G6-CD28 with Anti-CD3 mAb
and A1G4 Increases IL-2Ra Expression and IL-2 Produc-
tion. The stimulation of T cells with anti-CD3 and anti-
CD28 mAbs leads to enhanced T cell proliferation associ-
ated with increased IL-2Ra (CD25) expression and IL-2
secretion (40–42). Therefore, we examined the effect of
A1G4 on IL-2R expression and IL-2 secretion in trans-
duced primary T lymphocytes. Peripheral blood T lym-
phocytes were transduced with GaLV-pseudotyped recom-
binant retrovirus after mitogen activation, as described (26).
3 d after cocultivation with the producers PG13/3G6-
CD28, PG13/3G6-CD28TR, and PG13/NTP, 28–40%
of the CD31 cells stained positively for the vector-encoded
receptor in both CD41 and CD81 subsets, as shown in Fig. 2.
CD31 lymphocytes represent 94–98% of the cells after 7 d of
culture under these conditions (reference 25, and data not
shown). The three groups of cells maintained in 10 U/ml of
IL-2 expanded at the same rate (data not shown). Gene
transfer was confirmed by Southern blot analysis, which in-
dicated that A1G41 cells harbored on average one inte-
grated vector copy per cell (data not shown). As shown in
Table 2, the stimulation of primary T cells with OKT3 and
A1G4 increased IL-2R expression as effectively as OKT3
and anti-CD28 mAb in the 3G6-CD28–transduced popu-
lation. A1G4 had no effect on the NTP-transduced T cells
and a very modest effect on CD28TR1 cells. We next ex-
amined IL-2 production by T cells treated with A1G4/
OKT3, 9.3/OKT3, or OKT3 alone. Stimulation with
OKT3 plus A1G4 increased IL-2 production only in 3G6-
CD28–transduced T cells. The stimulation with A1G4 led
to an almost equal level of IL-2 secretion as with the mAb
9.3, although the 3G6-CD281 cells only represented 20%
of the total cell population. Therefore, we concluded that
the A1G4 mAb provided a progression signal leading to
enhanced IL-2R expression and IL-2 production in human
primary T lymphocytes transduced with the 3G6-CD28
receptor.
3G6-CD28–transduced Primary T Lymphocytes Selectively
Survive CD3-dependent Cell Death in the Presence of A1G4.
It has been previously reported that activated T cells un-
dergo apoptosis after cross-linking their TCR if they are
activated in a nonresting stage (19–23). This effect can be
Table 1. Tumor-associated Antigen GD2 Specifically Potentiates IL-2 Production by 3G6-CD28–transduced Jurkat T Cells Activated with 
Immobilized OKT3
IL-2 production (pg/ml)
—
—
9.3
—
A1G4
—
EL4GD22
5:1
—
EL4GD22
1:1
—
EL4
5:1
—
EL4
1:1
—
EL4
5:1
F(ab9)2*
EL4
1:1
F(ab9)2*
3G6-CD28 47 6 15 577 6 79 189 6 57 39 6 6 49 6 4 317 6 33 138 6 22 15 6 5 19 6 2
3G6-CD28TR 11 6 9 490 6 22 4 6 52  6  17  6  52  6  44  6  24  6  24  6  2
NTP 5 6 5 499 6 32 11 6 2 ,17   6  5 ,1 ,1 ,18   6  3
Results are the means 6 SD obtained from duplicates. The NTP marker was used as an irrelevant control that could be monitored for cell-suface ex-
pression in parallel to 3G6-CD28 and 3G6-CD28TR. T cells (2.5 3 105/ml) were incubated with OKT3 (10 mg/ml, immobilized on sheep anti–
mouse beads [3 beads/cell]) and stimulated with soluble 9.3 (ascites 1:1,000), A1G4 (2 mg/ml), EL4, or the GD2
2 variant EL4GD22.
*In anti-GD2 blocking conditions, EL4 cells were preincubated with anti-GD2 F(ab9)2 fragment 3F8 (10 mg/ml). After 24 h, supernatants were col-
lected, and IL-2 was measured by ELISA.
Figure 2. Retroviral gene transfer of
3G6-CD28, 3G6-CD28TR, and NTP in
human primary lymphocytes. PBLs were
stained 72 h after retroviral infection with
antibodies to CD8 (x-axis) and either A1G4
mAb to stain 3G6-CD28 and 3G6-
CD28TR or 20.4 mAb to stain NTP (y-
axis). Staining with secondary antibody
alone (GAR-PE; A) indicates the back-
ground staining. Staining with A1G4 (anti-
idiotype; B and C) and with 20.4 (anti–
NTP; D), followed by the corresponding
PE conjugates.623 Krause et al.
prevented by balanced CD3 and CD28 signaling. To ex-
amine whether cross-linking 3G6-CD28 with A1G4 mAb
could mimic CD28-mediated survival, we took advantage
of a model system in which T cells stimulated with anti-
CD3 mAb undergo apoptosis (43–45). Primary T lympho-
cytes transduced with NTP, 3G6-CD28, or 3G6-CD28TR
were kept for 3 d under the following conditions: without
antibody, with OKT3 (to trigger apoptosis), with OKT3
and 9.3 (to prevent apoptotic cell death through endoge-
nous CD28 signaling), or with OKT3 and A1G4 (to pre-
vent apoptotic cell death in cells expressing the 3G6-CD28
chimeric molecule). The medium included IL-2 at 10 U/
ml to prevent cell death due to cytokine deprivation. On
day 3, the T cells were released from the cross-linking con-
ditions, and cell viability was measured as shown in Fig. 3;
cell viability decreased in the presence of the plate-bound
OKT3, but was preserved in all groups by the addition of
anti-CD28 antibody. A1G4 maintained viability only in
the 3G6-CD28–transduced T cell population (which were
z30% A1G41). Thus, cross-linking 3G6-CD28 with the
mAb A1G4 increased the survival of these lymphocytes
cultured under proapoptotic conditions as effectively as the
addition of anti-CD28 antibody.
A1G4 mAb Induces Preferential Expansion of 3G6-CD28–
transduced Primary T Lymphocytes. The PBLs transduced with
either 3G6-CD28 or 3G6-CD28TR were plated 5 or 6 d
after gene transfer in the presence of soluble OKT3 (10 ng/ml)
alone or in addition soluble A1G4 or 9.3 mAb. The fraction
of CD31A1G41 cells was monitored over 12 d. As shown
in Fig. 4 B, neither of these three culture conditions in-
creased the percentage of cells expressing 3G6-CD28TR in
12 d. The 3G6-CD28–transduced T cells also remained
z30% A1G41 when cultured in either OKT3 or OKT3
plus anti-CD28 antibodies, but steadily increased over time
in the presence of OKT3 and A1G4 antibodies (Fig. 4 A).
These data strongly suggest that the engagement of 3G6-
CD28 with the antiidiotypic antibody A1G4 provides a
powerful costimulatory signal dependent on the cytoplas-
mic domain of CD28, resulting in the selective stimulation
of the transduced T cells.
Corecognition of MHC–Peptide Complexes and GD2 Selectively
Activates PBLs Expressing 3G6-CD28. To examine whether
Table 2. A1G4 Potentiates IL-2 Production and IL-2Ra Expression by 3G6-CD28–transduced T Cells Stimulated with
Immobilized OKT3
IL-2Ra expression* IL-2 secretion
Medium OKT3 OKT3/9.3 OKT3/A1G4 Medium OKT3 OKT3/9.3 OKT3/A1G4
% pg/ml
3G6-CD28 5 20 65 70 ,0.1 3.2 16 13
3G6-CD28TR 5.5 25 60 35 ,0.1 3.5 25 2.6
NTP 2 15 75 13 ,0.2 2.7 8.8 4.5
Primary T cells (105/ml) transduced 4–12 d earlier were stimulated for 24 h with medium or plate-bound OKT3, with or without soluble anti-
CD28 or A1G4 mAb on anti–mouse/anti–rat IgG–coated plates. Cells were stimulated with OKT3 (2 mg/ml) and 9.3 (ascites 1:1,000) or A1G4 (2
mg/ml). After 24 h, the cells were dual-stained with A1G4 to identify the transduced subpopulations and with anti-CD25 mAb to measure the ex-
pression of the IL-2R by FACSÒ. After 48 h, supernatants were collected, and IL-2 activity was measured by ELISA. Data represent one of two in-
dependent experiments.
*Expressed as the percentage of CD251 cells in the A1G41 or NTP1 fraction.
Figure 3. 3G6-CD28–transduced primary T lymphocytes selectively
survive CD3-dependent cell death in the presence of A1G4. Primary T
lymphocytes transduced with NTP, 3G6-CD28, or 3G6-CD28TR were
kept for 3 d under one of the following conditions: medium without an-
tibody, with OKT3, with OKT3 plus 9.3, or with OKT3 plus A1G4. On
day 3, the T cells were released from the cross-linking conditions, and cell
viability was measured by trypan blue exclusion and FACSÒ analysis. The
data represent the mean 6 SD of four experiments. Cell viability decreased in
the presence of the plate-bound OKT3 from 77 6 9% to 47 6 7% in the
NTP-transduced T cells, and from 77 6 8% to 56 6 4 and 54 6 7% in the
3G6-CD28 and 3G6-CD28TR–transduced groups, respectively. Viability
was unchanged by the addition of A1G4 to NTP- and 3G6-CD28TR–
transduced T cell groups (51 6 3 and 53 6 7%, respectively), but increased
to 77 6 7% in the 3G6-CD28–transduced T cell populations (which were
z30% A1G41). Survival in all three groups was comparable in the pres-
ence of anti-CD3 and anti-CD28 antibodies (85 6 8%).624 Antigen-dependent Costimulation Selectively Enhances Lymphocyte Survival
engagement of 3G6-CD28 by cell-bound GD2 antigen
could activate primary T cells recognizing target cells through
their TCR, we established an allogeneic coculture system.
The genetically modified primary T cells were cultured with
fibroblasts expressing an allogeneic MHC class I molecule
(HLA A2.1), either alone or together with human B7.1 or
GD2. Peripheral blood T lymphocytes from HLA A2.12
donors were transduced with 3G6-CD28, 3G6-CD28TR,
or NTP, and cocultured for 12 d as described in Materials
and Methods with irradiated fibroblasts. CD41 and CD81
lymphocytes were analyzed for transgene expression by
FACSÒ analysis on days 6 and 12. As shown in Fig. 4,
CD81 T cells transduced with 3G6-CD28 remained a con-
stant fraction of all T cells (10 6 2%) when cocultured ei-
ther with 3T3 cells alone, 3T3-A2.1, 3T3-A2.1/B7, or
3T3-GD2, but steadily increased to 32 6 4% by day 12 if
exposed to 3T3-A2.1/GD2 (Fig. 4 C). Under the same
conditions, the fraction of cells expressing 3G6-CD28TR
(Fig. 4 D) or NTP (data not shown) remained unchanged.
Thus, the increase in the fraction of 3G6-CD281 CD81 T
cells required both HLA A2.1 and GD2, which, on the
other hand, had no effect on the transduced CD41 subset
(Fig. 4 C). The same result was achieved in cultures of
transduced CD81 T cells in the absence of CD41 cells
(data not shown). These data establish that the engagement
of 3G6-CD28 with cell-surface GD2 antigen provides a
powerful costimulatory signal to T cells specific for GD2
1
target cells.
To provide the CD28 costimulatory signal to T lympho-
cytes that recognize target cells which lack B7 but express
the GD2 antigen, we generated a GD2-specific, CD28-like
fusion receptor. The fusion receptor 3G6-CD28 comprises
the scFv derived from the GD2-specific mAb 3G6 as its ex-
tracellular domain and most of the human CD28 molecule.
Our studies focused on human polyclonal primary T cells
that were initially mitogen-activated to enable retroviral-
mediated gene transfer. We demonstrated that 3G6-CD28
acts as an antigen-specific CD28-like receptor, augmenting
IL-2 secretion upon contact with GD2
1 tumor cells and se-
lectively conferring increased survival to PBLs cultured un-
der proapoptotic conditions. Antigen-dependent costimu-
lation could be useful in several ways. One is to sustain the
survival and function of T cell clones specific for defined
target cells that express the appropriate MHC and peptide
as well as GD2 antigen. Antigen-dependent costimulation
could also be useful in polyclonal lymphocytes, acting to
select from a heterogeneous population of T cells those that
are able to recognize target cells through their TCR. As
shown in Fig. 4, the expression of 3G6-CD28 does provide
for the preferred expansion of transduced T cells engaging
their TCR on GD2
1 target cells. Antigen-dependent CD28
signaling may also be useful to activate an expanded reper-
toire of tumor-reactive T cells by lowering the threshold
antigen density necessary for appropriate T cell activation
(14, 46). Furthermore, 3G6-CD28 may be useful to target
and sustain the activity of natural killer cells (47) against
GD2
1 tumor cells. Our data suggest that the concept of an-
tigen-dependent costimulation could be extended to other
cell-surface antigens.
Figure 4. Antiidiotypic mAb A1G4 and cell-bound GD2 provide co-
stimulatory signals to 3G6-CD28–transduced human primary T lympho-
cytes. (A and B) Primary T lymphocytes transduced with 3G6-CD28 or
3G6-CD28TR were cultured with soluble OKT3 (10 ng/ml) alone or
with the addition of soluble A1G4 or 9.3 mAb as described in Materials
and Methods. The percentage of transduced cells was measured by
FACSÒ analysis on days 6 and 12. When cultured in the presence of
OKT3 and A1G4 antibodies, T lymphocytes transduced with 3G6-CD28
increased from 30% A1G41 on day 0 to 60% on day 6 and to 88% on day
12, but remained at z30% when cultured otherwise (data represent one
of three independent experiments). (C and D) HLA A2.12 primary T
lymphocytes transduced with 3G6-CD28 (C) or 3G6-CD28TR (D)
were cocultured in triplicate wells with irradiated monolayers of fibro-
blasts as described in Materials and Methods. The fraction of A1G41 cells
was measured by FACSÒ analysis in both CD41 and CD81 subsets on
days 6 and 12. In cultures with 3T3-A2.1/GD2 the percentage of
CD81A1G41 T cells in the 3G6-CD28–transduced population increased
from 10 6 2% on day 0 to 15 6 2% on day 6 and to 32 6 4% on day 12
(C). The percentage of CD41A1G41 cells in the CD41 T cell population
remained unchanged under all of these coculture conditions (data not
shown). Data represent one of three independent experiments.
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